AB-CHMINACA

AB-CHMINACA

Systematic (IUPAC) name
N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
Legal status
Legal status	CA: Schedule II DE: Anlage II (Prohibited) US: Schedule I
Identifiers
CAS Number	1185887-21-1
PubChem	CID 70969900
ChemSpider	30646774
Chemical data
Formula	C20H28N4O2
Molar mass	356.46 g/mol
SMILES CC(C)[C@@H](C(=O)N)NC(=O)c1c2ccccc2n(n1)Cc3ccc(cc3)F
InChI InChI=1S/C20H21FN4O2/c1-12(2)17(19(22)26)23-20(27)18-15-5-3-4-6-16(15)25(24-18)11-13-7-9-14(21)10-8-13/h3-10,12,17H,11H2,1-2H3,(H2,22,26)(H,23,27)/t17-/m0/s1 Key:AKOOIMKXADOPDA-KRWDZBQOSA-N

AB-CHMINACA is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB₁ receptor (Ki = 0.78 nM) and CB₂ receptor (Ki = 0.45 nM) and fully substitutes for Δ⁹-THC in rat discrimination studies, while being 16x more potent.^[1][2]

Side Effects

There have been a number of reported cases of seizures, deaths, and psychotic episodes in relation to this synthetic cannabinoid.^{[3][4][5][6][7][8][9]}

Legal status

As of January 20, 2015 AB-CHMINACA is a Schedule I controlled substance in the United States.^[10]

AB-CHMINACA is an Anlage II controlled substance in Germany as of May 2015.^[11]

As of October 2015 AB-CHMINACA is a controlled substance in China.^[12]

AB-CHMINACA is illegal in Switzerland as of December 2015.^[13]

See also

• 5F-AB-PINACA
• 5F-ADB
• 5F-AMB
• AB-FUBINACA
• AB-CHFUPYCA
• AB-PINACA
• ADB-CHMINACA
• ADB-FUBINACA
• ADB-PINACA
• ADBICA
• APICA
• APINACA
• MDMB-CHMICA
• MDMB-CHMINACA
• MDMB-FUBINACA
• PX-3

References

1. Jenny L Wiley, Julie A Marusich, Timothy W Lefever, Kateland R Antonazzo, Michael T Wallgren, Ricardo A Cortes, Purvi R Patel, Megan Grabenauer, Katherine N Moore, and Brian F Thomas (June 2015). "AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice". Journal of Pharmacology and Experimental Therapeutics 354: 328–39. doi:10.1124/jpet.115.225326. PMC: 4538877. PMID 26105953.
2. AB-CHMINACA, Cayman Chemicals
3. "N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3- carboxamide (AB-CHMINACA), N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H- indazole-3-carboxamide (AB-PINACA) and [1-(5-fluoropentyl)-1H-indazol-3- yl](naphthalen-1-yl)methanone (THJ-2201). Background Information and Evaluation of ‘Three Factor Analysis’ (Factors 4, 5, and 6) for Temporary Scheduling." (PDF). Drug Enforcement Administration. December 2014. Retrieved 7 August 2015.
4. Jamie Merrill (5 June 2015). "Vertex: Police warn of 'ticking time bomb' of potentially lethal cannabis substitute". The Independent. Retrieved 2 July 2015.
5. Jordan Trecki, Roy R. Gerona, Michael D. Schwartz (July 2015). "Synthetic Cannabinoid–Related Illnesses and Deaths". New England Journal of Medicine 373 (2): 103–107. doi:10.1056/NEJMp1505328. PMID 26154784.
6. Amin Wurita, Koutaro Hasegawa, Kayoko Minakata, Kunio Gonmori, Hideki Nozawa, Itaru Yamagishi, Osamu Suzuki, Kanako Watanabe (July 2015). "Identification and quantification of metabolites of AB-CHMINACA in a urine specimen of an abuser". Legal Medicine. doi:10.1016/j.legalmed.2015.07.011.
7. Brittany Schock (30 September 2015). "No criminal charges in March death of Terrance Moxley". Richland Source. Retrieved 2 October 2015.
8. Joseph A. Tyndall, Roy Gerona, Giuliano De Portu, Jordan Trecki, Marie-Carmelle Elie, Judith Lucas, John Slish, Kenneth Rand, Lindsay Bazydlo, Martina Holder, Matthew F. Ryan, Paul Myers, Nicole Iovine, Michelle Plourde, Emily Weeks, James R. Hanley, Greg Endres, Danielle ST Germaine, Paul J. Dobrowolski, Michael Schwartz (November 2015). "An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA". Clinical Toxicology 53: 950–956. doi:10.3109/15563650.2015.1100306.
9. Janez Klavž, Maksimiljan Gorenjak, Martin Marinšek (August 2016). "Suicide attempt with a mix of synthetic cannabinoids and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC". Forensic Science International 265: 121–124. doi:10.1016/j.forsciint.2016.01.018.
10. Drug Enforcement Administration, Department of Justice (2015). "Schedules of controlled substances: Temporary placement of three synthetic cannabinoids into schedule I. Final order". Federal register 80 (20): 5042–7. PMID 25730924.
11. "Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) Anlage II (zu § 1 Abs. 1) (verkehrsfähige, aber nicht verschreibungsfähige Betäubungsmittel)". Retrieved 22 June 2015.
12. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
13. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien". Der Bundesrat.